


Arvinas Email Formats
Biotechnology Research • New Haven, Connecticut, United States • 201-500 Employees
Arvinas Email Formats
Arvinas uses 3 email formats. The most common is {first initial}.{last name} (e.g., j.doe@arvinas.com), used 84.6% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}.{last name} | j.doe@arvinas.com | 84.6% |
{first name}.{last name} | john.doe@arvinas.com | 12.2% |
{2char} | {2char}@arvinas.com | 2.1% |
Key Contacts at Arvinas
Deborah Kroeger
Senior Director, Talent Acquisition
Will Kattell
Associate Director, Talent Acquisition
Joseph Reo
Senior Director
Rushad E. Karanjawala
Director Ethics & Compliance
Milky Florent
Executive Director, Regulatory Affairs
Tim Bye
Senior Director, Commercial Operations
Stacey Versavel
Senior Medical Director, Neurology, Medical Affairs
Joseph Sciacchitano
Us Head, Senior Director Patient Support Services | Market Access
Christine Edwards
Associate Director, Talent Acquisition
Cathy Consolo
Executive Director National Payer Accounts
Company overview
| Headquarters | 395 Winchester Ave., 5 Science Park, New Haven, Connecticut 06511, US |
| Phone number | +12035351456 |
| Website | |
| NAICS | 541714 |
| SIC | 283 |
| Founded | 2013 |
| Employees | 201-500 |
| Socials |
About Arvinas
Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its PROTAC Discovery Engine to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; and ARV-102, targeting LRRK2 for neurodegenerative disorders. Based in the biotech hub of New Haven, CT, Arvinas is driven by an industry-leading team dedicated to improving the lives of people living with serious diseases. For more information, visit www.arvinas.com. Community Guidelines: http://bit.ly/ArvinasCG
Employees by Management Level
Total employees: 201-500
Seniority
Employees
Employees by Department
Arvinas has 174 employees across 17 departments.
Departments
Number of employees
Arvinas Tech Stack
Discover the technologies and tools that power Arvinas's digital infrastructure, from frameworks to analytics platforms.
Caching
JavaScript libraries
JavaScript libraries
Maps
WordPress themes
Page builders
JavaScript libraries
JavaScript libraries
Webmail
Programming languages
Security
Frequently asked questions
4.8
40,000 users



